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BONE MORPHOGENETIC PROTEIN 2 STIMULATES 
ARTICULAR CARTILAGE PROTEOGLYCAN SYNTHESIS IN VIVO
BUT DOES NOT COUNTERACT INTERLEUKIN-la EFFECTS
ON PROTEOGLYCAN SYNTHESIS AND CONTENT
i
PETER M. v a n  d e r  KRAAN, and WIM B. v a n  d e n  BERG
Objective. To study the effect of bone morphoge­
netic protein 2 (BMP-2) on articular cartilage proteo­
glycan (PG) synthesis in vivo and to investigate whether 
BMP-2 is able to counteract the effects of interleukin-1 
(IL-1) on articular cartilage PG synthesis and content.
Methods. BMP-2 alone or in combination with 
IL-la was injected into murine knee joints. PG synthe­
sis was measured by 35S-sulfate incorporation using an 
ex vivo method or autoradiography. Cartilage PG con­
tent was analyzed by measuring Safranin O staining 
intensity on histologic sections.
Results. BMP-2 appeared to be a potent stimula­
tor of articular cartilage PG synthesis in vivo. However, 
BMP-2 was not able to counteract the deleterious effects 
of IL-la on articular cartilage PG synthesis and con­
tent. In addition, intraarticular injections of BMP-2 
induced chondrophytes.
Conclusion. Although BMP-2 is a very potent 
stimulator of cartilage PG synthesis in vivo, the thera­
peutic applications of BMP-2 are limited due to the 
inability of BMP-2 to counteract the effects of IL-I and 
the induction of chondrophytes.
Rheumatoid arthritis (RA) is a disease charac­
terized by chronic inflammation of the joints. The dis-
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ease causes cartilage degradation, which results in the 
loss of joint function. An early event in the process of 
cartilage degradation is depletion of proteoglycans (PG) 
from articular cartilage. Interleukin 1 (IL-1) is an im­
portant mediator in this process. IL-1 is able to enhance 
PG degradation and to suppress PG synthesis (1-4). 
Moreover, studies in which IL-1 was neutralized during 
experimental arthritides demonstrated that IL-1 is di­
rectly involved in the inhibition of articular cartilage PG 
synthesis (4-7).
Factors which are able to counteract the effects 
of IL-1 on chondrocyte metabolism or which are able to 
stimulate the replenishment of PGs in the depleted 
matrix could be of significant therapeutic value. In this 
respect, bone morphogenetic proteins (BMPs) seem 
promising. BMPs belong to the transforming growth 
factor 18 (TGF/3) superfamily (8,9). This superfamily 
consist of dimeric molecules, each monomer of which 
contains 7 conserved cysteine residues (10). The proteins 
signal by serine/threonine kinases (8,11).
One of the members of the BMP family with 
potential therapeutic value is bone mor 
protein 2 (BMP-2). BMP-2 has been demonstrated to be
ienetic
a stimulator of chondrocyte and
differentiation (12-15). BMP-2 is a potent stimulator of 
PG synthesis by articular cartilage explants in vitro (12), 
but until now, no in vivo data about the effects of BMP-2 
on articular cartilage PG synthesis have been available. 
Neither have any data been published about the ability 
of BMP-2 to counteract the effects of IL-1 on articular 
cartilage. We therefore studied the effect of BMP-2 on 
murine articular cartilage PG synthesis in vivo and 
investigated the of BMP-2 to counteract the 
effects of IL-1 on articular cartilage PG synthesis and 
content.
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MATERIALS AND METHODS
Animals. Male C57B1/6 mice between ages 8 and 12 
weeks were used. Mice were fed a standard diet and tap water 
ad libitum.
Growth factors and cytokines. Recombinant murine 
IL-1 a (0.48 mg/ml in phosphate buffered saline, pH 7.4) and 
recombinant human TGF/31 (0.1 mg/ml in 20 mM NaOAc, pH 
5.0) were kindly provided by Pfizer Central Research (Groton, 
CT) and Genentech (South San Francisco, CA), respectively. 
Recombinant human BMP-2 (2.27 mg/ml in 0.5M arginine, 10 
mM histidine, pH 6.5) was supplied by 
(Cambridge, MA). To prevent loss of protein due to adherence 
to plastic, only siliconized tubes and tips were used.
Intraarticular injections. To study the effect of BMP-2 
on articular cartilage PG synthesis in vivo, 6 ¡x\ of physiologic 
saline plus 0.1% bovine serum albumin including recombinant 
human BMP-2 (2-1,000 ng) was injected into the joint cavity of 
the right knee. The ability of BMP-2 to counteract the effects 
of IL-1 on articular cartilage PG synthesis and content was 
studied by injecting IL-1 a  (10 ng), either alone or in the 
presence of BMP-2 (200-1,000 ng). The dose of 10 ng IL-1 a 
has been demonstrated to suppress articular cartilage PG 
synthesis after a single injection and to induce significant PG 
depletion in multiple injection protocols (2). A single injection 
was given, or 3 injections were given on alternate days. Since 
we have previously demonstrated that TGF/31 is able to 
counteract the effects of IL-1 on articular cartilage PG synthe­
sis and content (16,17), we used coinjections of IL-lcx (10 ng) 
and TGF/31 (200 ng) as positive controls.
Histology. Whole knee joints were dissected and fixed 
for 7 days in phosphate buffered formalin. The fixed knee 
joints were decalcified (5% formic acid) and dehydrated by an 
automated tissue processing apparatus (VIP; Miles Scientific, 
Naperville, IL). After embedding in paraffin wax, semiserial 
frontal knee sections (6 /xm) were prepared and mounted on 
gelatin-coated slides. Paraffin was removed by xylol and etha­
nol, and sections were stained with Safranin O and fast green
(18). Safranin O staining, a semiquantitative marker of PG 
depletion, was measured using an automated image analysis
(VIDAS; Kontron Electronics, Munich, Germany)
(19). Fast green staining was neutralized by use of a green 
filter. Optical density was examined in the noncalcified carti­
lage of the patella. Measurements were corrected for chondro­
cyte lacunae. Staining values were corrected for background 
staining, as measured in PG-depleted patellar cartilage in
r stain was no PG etion was
induced by intraarticular injection of papain (19), Each exper­
imental group contained at least 8 knee joints, of which 3 
semiserial sections were analyzed.
Autoradiographic analysis of -,5S-suIfate incorporation 
was performed as described (18). Radiolabeled sulfate (75 
iu-Ci) was injected intraperitoneally 6 hours before dissection of
; joints. : processing, 6-/u,m sections were
prepared and mounted on gelatin-coated slides. These were
in Ks emulsion (Ilford Basildon, Essex, UK) and 
exposed for 3 or 5 weeks. After this period, the slides were 
developed and stained with hematoxylin and eosin.
Determination of patellar cartilage PG synthesis. Pro­
teoglycan synthesis was measured ex vivo according to the 
method of van den Berg et al (20). Whole patellae were
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Figure 1, Patellar cartilage synthesis of proteoglycans in untreated 
knees (solid bars) and in knees on day 2 after a single mtraarticular 
Injection of vehicle (horizontal-striped bars), bone morphogenetic 
protein 2 (200 ng) (hatched bars), or transforming growth factor (i\ 
(200 ng) (vertical striped bars) with (A) or without (B) coinjection of 
10 ng interleukin-1«. S-sulfate Incorporation (mean
age of incorporation in untreated knees; n ; ■ ft) was measured after an
ex vivo pulse-labeling of isolated patellae with S-sulfate. S-sulfate 
incorporation by central and peripheral areas of untreated knees was
comparable (400--700 cmp). * P - ii" 0.05 versus vehicle-injected
knees, by Student’s Mest. (Note: y-axis scales differ in A and B.)
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dissected from the knee joints and pulse-labeled (3 hours at 
37°C) with 3SS-sulfate (30 juCi/ml). Subsequently, they were 
washed, fixed in ethanol, and decalcified in formic acid, After 
décalcification of the patellae, the entire cartilage was stripped 
off, and a 0.2 mm2 round section was punched out of the center 
(central part) that remained in the peripheral area (21). The 
central and peripheral areas of the patellar cartilage were 
dissolved and 33S-incorporation was counted by liquid scintil­
lation counting. Each experimental group contained at least 6
RESULTS
Effect of BMP-2 on articular cartilage PG syn­
thesis in vivo. Intraarticular injection of BMP-2 (2-1,000 
ng) resulted in stimulation of patellar cartilage PG 
synthesis, which was maximal 2 days after injection. The 
effect of BMP-2 on PG synthesis was dose dependent, 
with a maximum stimulation of 250% at a dosage of 
>200 ng (data not shown). To investigate whether 
BMP-2 has differential effects on PG synthesis in the 
central and peripheral areas of the patella, PG synthesis 
of both areas was measured separately.
BMP-2 stimulated patellar cartilage PG synthesis 
by both the central and peripheral areas equally (Figure 
1A). On day 2 after intraarticular injection of TGF/31 
(200 ng), no significant effect on articular cartilage PG 
synthesis was noted (Figure 1A).
Absence of counteraction by BMP-2 of IL-la- 
incluced PG synthesis inhibition. Since BMP-2 appeared 
to be a potent stimulator of patellar PG
synthesis, we evaluated whether BMP-2 was able to 
counteract the suppressive effect of IL-1 on cartilage PG 
synthesis. IL-1 a (10 ng) was injected into murine knee 
joints in the presence or absence of 200 ng of BMP-2. 
Two days after intraarticular injection of IL-1 a, total 
patellar PG synthesis was ~40% lower than in controls. 
Suppression of PG synthesis by IL-la alone was higher 
in the central part (mean ±  SD 69 ±  20%) than in 
the peripheral part (16 ±  33%) (Figure IB). Simulta­
neous injection of 10 ng IL-1 a and 200 ng BMP-2 
resulted in suppression of PG synthesis to a 
similar to that induced by IL-1 a alone (Figure 
Coinjection with higher concentrations of BMP-2 (up to 
1 [xg) had no effect on IL-1 a-induced suppression (data 
not shown).
These results demonstrate that although BMP-2 
is a potent stimulator of articular cartilage PG synthesis, 
it is unable to counteract the inhibition of articular 
cartilage PG synthesis induced by IL-1 a. Moreover, 
these results also indicate that the effects of BMP-2 on 
cartilage PG synthesis are blocked when chondrocyte 
metabolism is affected by IL-1 a. In parallel with BMP-2,
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Figure 2. Patellar cartilage synthesis of proteoglycans in untreated 
knees (solid bars) and in knees on day 2 after 3 intraarticular injections 
of vehicle (horizontal-striped bars), bone morphogenetic protein 2 
(200 ng) (hatched bars), or transforming growth factor /31 (200 ng) 
(vertical striped bars) with (A) or without (B) coinjection of 10 ng 
interleukin-la .  (IL -la). 35S-sulfate incorporation was measured as 
described in Figure 1, and expressed as the mean ± SD percentage of 
untreated knees (n =  6). 35S-sulfate incorporation by central and 
peripheral areas of untreated knees was comparable (400-700 cmp). * 
= P <  0.05 versus vehicle-injected knee joints; #  = P <  0.05 versus 
IL-la-injected knees, by Student’s f-test. (Note: y-axis scales differ in 
A and B).
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to TGF/31 resulted in stimulation of articular cartilage 
PG synthesis, while short-term exposure had no effect 
on PG synthesis (22). We sought to determine whether 
long-term, rather than short-term, exposure of cartilage 
to BMP-2 could counter IL-la-induced suppression of 
PG synthesis. We therefore gave 3 coinjections on 
alternate days. BMP-2 (200 ng) and TGF/31 (200 ng) 
stimulated articular cartilage PG synthesis in both the 
central and peripheral areas of the patellar cartilage 
(Figure 2A). Coinjections of IL-la (10 ng) and BMP-2 
(200 ng) resulted in strong suppression (>60%) of PG 
synthesis in the central part of the patella, which was not 
significantly different from the synthesis after 3 injec­
tions with IL -la alone (Figure 2B). This indicates that 
long-term exposure of cartilage to BMP-2 is also not 
able to counteract the effects of IL-la.
In contrast to the central region, PG synthesis in 
the peripheral region in the mice injected with IL-la  
alone was not different from that of the controls. Knee 
joints injected with IL-la (10 ng) and BMP-2 (200 ng) 
showed a significant stimulation of PG synthesis in the 
peripheral area of the patella. In contrast to BMP-2, 
injections of TGF01 (200 ng) in the presence of IL-la  
(10 ng) resulted in stimulation of PG synthesis in both 
the central and peripheral regions of the patellar carti­
lage (Figure 2B), demonstrating that TGF/31 is able to 
counteract IL-la-induced suppression of articular car­
tilage PG synthesis after long-term exposure.
Autoradiographic analysis of local effects of 
BMP-2 on PG synthesis. To investigate the effects of 
BMP-2 on chondrocytes from various sites of the joint, 
PG synthesis was studied by autoradiography of histo­
logic sections. Figure 3 shows autoradiographs of the 
central regions of the patellar cartilage and the facing 
femoral cartilage 1 day after 3 injections. BMP-2 (200 
ng) stimulated PG synthesis in femoral cartilage to a 
similar extent as in patellar cartilage and homogeneously 
throughout the articular cartilage (Figure 3B). Injections 
of IL-la (10 ng) resulted in suppression of PG synthesis 
in both the patellar and femoral cartilage (Figure 3D). 
Coinjections of IL-la (10 ng) and BMP-2 (200 ng) 
suppressed PG synthesis in patellar and femoral carti­
lage to a similar extent as injections of IL-la alone 
(Figure 3E), demonstrating that BMP-2 did not coun­
teract the IL-la-induced inhibition of PG synthesis in 
either the patellar or the femoral cartilage. In contrast, 
coinjections of IL-la (10 ng) and TGF/31 (200 ng) 
resulted in stimulation of PG synthesis in both the 
patellar and femoral cartilage (Figure 3F), as compared
Table 1. Safranin O staining of histologic sections of patellar carti­
lage on day 1 or day 4 after triple intraarticular injections*
% staining intensity
Injection Day 1 Day 4
Vehicle 100 ± 12 100 ± 16
Interleukin-la (10 ng) 69 ± 12f 76 ± I lf
+  BMP-2 (200 ng) 71 ±  12+ 77 ± 22+
+  TGF01 (200 ng) 67 ± 14+ 107 ± 21$
* Whole knee joints were dissected 1 or 4 days after triple intraartic­
ular injections. Histologic sections of patellar cartilage were stained 
with Safranin O and quantified using an automated image analyzer. 
Values were corrected for background staining, as measured in 
completely depleted pateltar cartilage. Each group contains at least 8 
knee joints, from which 3 histologic sections were analyzed. BMP-2 = 
bone morphogenetic protein 2; TGF/31 =  transforming growth factor 
j31.
t  P <  0.05 versus vehicle-injected knee joints, by Student’s i-test.
%P <  0.05 versus interleukin-1 a-injected knee joints, by Student’s 
i-test.
with injections of IL-la (Figure 3D). Similar
effects were demonstrated in the femorotibial joint (not 
shown).
Effect of BMP-2 on IL-la-induced PG depletion.
Changes in patellar cartilage PG content were measured 
after triple injections with IL-la alone or in combination 
with BMP-2 or TGF/31. The PG content of articular 
cartilage is reflected in the intensity of Safranin O 
staining of histologic sections. As shown in Table 1, 
significant loss of Safranin O staining was noted on day 
1 and day 4 after 3 injections of 10 ng IL-la. Injections 
with IL -la  (10 ng) in the presence of 200 ng BMP-2 
demonstrated that BMP-2 had no effect on patellar 
cartilage PG content neither on day 1 nor on day 4. 
Coinjections of IL -la  (10 ng) and TGF/31 (200 ng) 
resulted in an initial depletion of PGs (day 1 after 3 
injections) that was indistinguishable from the depletion 
induced by IL -la  alone. However, 4 days after the last 
injection, patellar cartilage Safranin O staining was 
significantly more intense in joints that had been in­
jected with both IL -la  and TGF/31 than in those injected 
with IL -la  alone. These results demonstrate that BMP-2 
does not modify IL-la-induced PG depletion and, in 
contrast to TGF/31, is not able to accelerate the replen­
ishment of PG in the depleted matrix.
Induction of chondrophytes by BMP-2. Histo­
logic sections of the knee joints demonstrated that 
intraarticular injection of BMP-2 (200 ng) resulted in the 
formation of new chondroid tissues (Figure 4B). These 
chondrophytes were predominately localized in the 
patellofemoral area. Chondrophytes were also induced 
after coinjections of IL-la (10 ng) and BMP-2 (200 ng) 
(Figure 4D). This indicates that although IL-la blocks
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after injection. The difference in kinetics between 
BMP-2 and TGF/31 indicates that in vivo, chondrocytes 
respond immediately to BMP-2, but the TGF/31 re­
sponses are dependent on a second mediator or on 
changes in chondrocyte reactivity to TGFjSl induced by 
the injected TGFjSl itself.
Although BMP-2 stimulated articular cartilage 
PG synthesis in vivo, it was unable to counteract the 
suppression of articular cartilage PG synthesis that was 
induced by 10 ng of IL-la. No significant effect of 
BMP-2 could be demonstrated in cartilage showing 
IL-l-induced inhibition of PG synthesis. However, it 
cannot presently be completely excluded that BMP-2 is 
able to counteract the effects of lower concentrations of 
IL-la. Other members of the BMP family have been 
reported to inhibit IL-l-induced suppression of articular 
cartilage PG synthesis in vitro. For example, BMP-7 
counteracted the effect of IL-la on chondrocyte PG 
synthesis in bovine cartilage explants (24). However, no 
data on the in vivo effects of BMPs on IL-l-induced 
suppression of articular cartilage PG synthesis have been 
published until now.
The lack of change in articular chondrocyte PG 
synthesis induced by BMP-2 in the presence of IL-la
(27-29), it was unable to inhibit IL-l-induced PG de­
pletion in vivo. The discrepancy between in vitro and in 
vivo findings could be attributed to mediators produced 
by synovial cells or by inflammatory cells that are 
attracted to the joint by coinjections of TGF/31 and 
IL -la (16).
The ability of BMP-2 to accelerate the replenish­
ment of PGs in IL-l-depleted cartilage was studied by 
measuring Safranin O staining intensity on day 4 after 3 
injections with IL -la . We demonstrated that BMP-2 did 
not enhance restoration of PG content in IL-l-depleted 
matrix at this time. In contrast to BMP-2, TGF/31 clearly 
stimulated repair in the depleted matrix. The different 
effects of BMP-2 and TGF/31 on the replenishment of 
PGs in the depleted matrix can be explained by the 
different abilities of BMP-2 and TGF/31 to counteract 
the IL-l-induced suppression of articular cartilage PG 
synthesis.
Intraarticular injections of BMP-2 resulted in the 
formation of new chondroid tissue, especially in the 
patellofemoral area. As we demonstrated previously, 
intraarticular injections of TGFjSl also induced chondro- 
phytes (22). Interestingly, BMP-2-induced chondrophytes 
are quite different from TGF/31-induced chondrophytes
indicates that the effect of BMP-2 on articular cartilage 
PG synthesis is blocked when chondrocyte metabolism is
(Van Beuningen et al: unpublished observations). The 
ability of BMP-2 to induce the formation of new carti-
aftected by IL-la. The mechanism of IL-l-induced 
BMP-2 nonresponsiveness is presently unclear. Down- 
regulation of BMP-2 receptors or blocking of intracell-
lage and bone has been demonstrated by the rat ectopic 
bone formation assay (9,30,31). Other members of the 
BMP family, such as BMP-3, BMP-4, BMP-5, and
ular signaling pathways by IL-1 are 2 possibilities. In BMP-7, are also able to induce new cartilage and bone in
contrast to BMP-2, TGF/31 was able to counteract 
IL-l-induced suppression of articular cartilage PG syn­
thesis, indicating that chondrocytes that are affected by 
IL-la still have the capability to react to TGF/3. These 
results indicate that IL -la obstructs the BMP-2, but not 
the TGF/31, signaling pathway in articular chondrocytes.
Members of the BMP family seem to have, at is a potent stimulator of articular cartilage PG synthesis, 
least in vitro, the potential to inhibit the synthesis of However, when chondrocyte metabolism is affected by
vivo (30-33). Although IL-la appeared to block the 
effects of BMP-2 on articular cartilage PG synthesis, the 
formation of chondrophytes was not inhibited by IL-la, 
which demonstrates that IL-1 does not block all BMP- 
2-mediated responses in the joint.
In summary, this studv demonstrates that BMP-2
PG-degrading enzymes and to inhibit PG breakdown 
itself. BMP-7 suppressed IL-l-induced up-regulation of 
collagenase (MMP-1) and stromelysin (MMP-3) mes­
senger RNA and counteracted the IL-l-induced inhibi­
tion of their natural inhibitor (TIMP) (26). BMP-3 and 
BMP-4 have been shown to inhibit PG degradation in 
cartilage explants cultured in vitro (23). We therefore 
examined the effects of BMP-2 on IL-l-induced PG 
depletion in articular cartilage. Safranin O staining of 
patellar cartilage on histologic sections demonstrated 
that BMP-2 did not affect IL-la-induced PG depletion. 
Although TGF/31 appears to be an inhibitor of the 
catabolic effects of IL-1 on articular cartilage in vitro
IL-la, the stimulatory effect of BMP-2 on PG synthesis 
is completely blocked. Because IL-1 is present in ar­
thritic joints (34-37), our results indicate that BMP-2
alone cannot be used to stimulate cartilage repair during
Although BMP-2 appears to be unable to 
stimulate cartilage repair when IL-1 is present, BMP-2 
might stimulate cartilage repair in the presence of IL-1 
inhibitors such as IL-1 receptor antagonist. In addition, 
BMP-2 could have the potential to stimulate cartilage 
repair in pathologic conditions, such as cartilage trauma, 
in which it is unlikely that IL-1 is involved. However, 
formation of chondrophytes might limit the therapeutic 
applications of BMP-2.
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